Story perspectives

FSSAI files three cases against Nestlé infant formula claims

By Drooid · Sep 18, 2026, 2:02 PM UTC · How we work

Summary

FSSAI Sues Nestlé

India’s Food Safety and Standards Authority (FSSAI) filed three adjudication cases against Nestlé India over infant nutrition products.
FSSAI said NAN Excella Pro Stage 1 and Lactogen Pro 1 breached Regulation 4(2) with false whey-protein and HMO claims.
A laboratory test found the follow-up formula’s biotin level below the 2020 requirement; a referral lab confirmed non-conformance.
Nestlé India said its products and labels were approved by an FSSAI expert committee and shares fell about 2% on Sep 18.

Summary

Nestlé Faces Notice

FSSAI has issued more than 150 notices to food firms recently, indicating heightened regulatory enforcement.
Nestlé India previously contested a 2015 FSSAI case over Maggi noodles labeling that led to a nationwide ban.
The Infant Milk Substitutes Act of 1992 prohibits direct-to-consumer advertising of infant formula, underpinning current claim bans.
The milk-and-nutrition segment’s share of turnover fell to 33.4% in FY26, down from 38.1% in FY25.

History

Historical Context

The Food Safety and Standards Act of 2006 merged earlier food laws and led to the creation of the Food Safety and Standards Authority of India on 5 September 2008. The authority then issued the Packaging and Labelling Regulation in 2011, requiring detailed nutrient disclosures and prompting a 45 % rise in compliance inspections by 2012. Ongoing enforcement now targets false protein claims in infant formula.

1 of 3

FSSAI Sues Nestlé

India’s Food Safety and Standards Authority (FSSAI) filed three adjudication cases against Nestlé India over infant nutrition products.
FSSAI said NAN Excella Pro Stage 1 and Lactogen Pro 1 breached Regulation 4(2) with false whey-protein and HMO claims.
A laboratory test found the follow-up formula’s biotin level below the 2020 requirement; a referral lab confirmed non-conformance.
Nestlé India said its products and labels were approved by an FSSAI expert committee and shares fell about 2% on Sep 18.

1 / 3